|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||309.38 g/mol g·mol−1|
|3D model (JSmol)|
Gevotroline (WY-47,384) is an atypical antipsychotic with a tricyclic structure which was under development for the treatment of schizophrenia by Wyeth-Ayerst. It acts as a balanced, modest affinity D2 and 5-HT2 receptor antagonist and also possesses high affinity for the sigma receptor. It was well tolerated and showed efficacy in phase II clinical trials but was never marketed.
(TCAs and TeCAs)